Exhibit 10.2

 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

AMENDMENT NO. 2

 

This Amendment No. 2 (“Amendment”), effective as of March 31, 2015 (the
“Effective Date”), entered into by and between (i) AMAG Pharmaceuticals, Inc.
(“AMAG” or the “Company”) and (ii) Sigma-Aldrich, Inc. (“SAFC”), amends that
certain Commercial Supply Agreement between AMAG and SAFC dated August 29, 2012
(the “Commercial Supply Agreement”), as amended October 3, 2013 (“Amendment
No. 1”), and collectively with the Commercial Supply Agreement, the
“Agreement”). Capitalized terms used but not defined in this Amendment will have
the meanings given them in the Agreement.

 

BACKGROUND

 

SAFC and AMAG desire to amend the Agreement as set forth in this Amendment.

 

Now, therefore, in consideration of the premises and the mutual covenants and
agreements contained herein, the Parties hereby agree as follows:

 

AMENDMENTS

 

1.              As set forth in Section 5.2 of the Commercial Supply Agreement,
the sales prices for Product Manufactured under the Agreement shall be the sales
prices in Appendix 3 to the Commercial Supply Agreement (subject to price
adjustment based on PPI in accordance with Section 5.5 of the Commercial Supply
Agreement); provided, however, and notwithstanding anything to the contrary in
this Agreement, that SAFC agrees to hold the sales prices firm, without any PPI
increases, as in effect on the date of this Amendment, through the end of [***].

 

2.              The Parties further agree that the first sentence of
Section 2.8(c) until and including the table below will be deleted and restated
as follows:

 

(c)                                  As set forth in Section 5.2 of the
Agreement, the sales prices for Product Manufactured under this Agreement shall
be the sales prices in Appendix 3; provided, however, beginning on [***] SAFC
will use commercially reasonable efforts to provide AMAG with the following
Product Pricing:

 

Amount Produced per Calendar Year (kg)

 

Price per kg Fe shipped from SAFC (USD)

0-180

 

[***]

181-360

 

[***]

361-540

 

[***]

541 or more

 

[***]

 

--------------------------------------------------------------------------------

 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

3.              The Parties further agree that in Section 2.8(d)(ii)(b) of the
Commercial Supply Agreement, which was added pursuant to Amendment No. 1, “If
after [***]” shall be deleted and restated as: “If after [***].”

 

CONFIDENTIAL

 

2

--------------------------------------------------------------------------------

 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

SIGNATURE PAGE TO AMENDMENT NO. 2

 

In Witness Whereof, the Parties by their authorized representatives have
executed this Amendment as of the Effective Date.

 

AMAG PHARMACEUTICALS, INC.

 

Sigma-Aldrich, Inc.

 

 

 

 

 

 

By:

/s/ Frank E. Thomas

 

By:

/s/ Gilles Cottier

 

 

 

 

 

Name:

Frank E. Thomas

 

Name:

Gilles Cottier

Title:

Chief Operating Officer

 

Title:

Vice President

 

CONFIDENTIAL

 

3

--------------------------------------------------------------------------------